A REVIEW OF TRIPTAN FORMULATIONS FOR THE TREATMENT OF MIGRAINE
DOI:
https://doi.org/10.22159/ijcpr.2025v17i5.7019Keywords:
Migraine, Triptan, Dosage form, Bioavailability, Method of preparation, HeadacheAbstract
Migraine is a severe headache that induces throbbing and pounding pain all over the head and is accompanied by sensitivity towards light, sound and touch. Triptans is one of the major class used to treat migraine. These are mainly employed in treating acute migraine conditions. This review paper focuses on comprehensive analysis of triptan-based treatments for migraine, with an emphasis on creating new dosage forms that would improve bioavailability and therapeutic effectiveness. This paper includes pharmacokinetics, mechanism of action and ability to target trigeminocervical system of almotriptan, naratriptan, rizatriptan, sumatriptan, and zolmitriptan. Innovative methods that have potential to boost medication transport to brain with less systemic exposure and quick relief from migraine symptoms are explained. It is finally concluded that triptan class is still a viable treatment option for migraine, with new dosage forms providing consistent therapeutic effect.
Downloads
References
1. Ong JJ, De Felice M. Migraine treatment: current acute medications and their potential mechanisms of action. Neurotherapeutics. 2018 Apr;15(2):274-90. doi: 10.1007/s13311-017-0592-1, PMID 29235068, PMCID PMC5935632.
2. Killoran PM, Capel V, D Aloisio V, Schofield A, Aczel T, Bolcskei K. Novel peptide calcitonin gene-related peptide antagonists for migraine therapy. J Pharm Pharmacol. 2023 Sep 23;75(12):1581-9. doi: 10.1093/jpp/rgad081, PMID 37742055, PMCID PMC10502456.
3. Diener HC, May A. New migraine drugs: a critical appraisal of the reason why the majority of migraine patients do not receive an adequate medication. Cephalalgia. 2024 Mar;44(3):3331024241228605. doi: 10.1177/03331024241228605, PMID 38520255.
4. Abdou EM, Kandil SM, Miniawy HM. Brain targeting efficiency of antimigrain drug-loaded mucoadhesive intranasal nanoemulsion. Int J Pharm. 2017;529(1-2):667-77. doi: 10.1016/j.ijpharm.2017.07.030, PMID 28729175.
5. Bohm PE, Stancampiano FF, Rozen TD. Migraine headache: updates and future developments. Mayo Clin Proc. 2018 Nov;93(11):1648-53. doi: 10.1016/j.mayocp.2018.09.006, PMID 30392545.
6. Humphrey PP. The discovery and development of the triptans a major therapeutic breakthrough. Headache. 2008 May;48(5):685-7. doi: 10.1111/j.1526-4610.2008.01097.x, PMID 18471110.
7. Macone AE, Perloff MD. Triptans and migraine: advances in use, administration, formulation and development. Expert Opin Pharmacother. 2017 Apr;18(4):387-97. doi: 10.1080/14656566.2017.1288721, PMID 28129702.
8. Cleveland Clinic. Migraine Headaches. Cleveland Clinic; 2023 Apr 18; Available from: https://my.clevelandclinic.org/health/diseases/5005-migraine-headaches#overview. [Last accessed on 03 May 2025].
9. Rose FC. The history of migraine from mesopotamian to medieval times. Cephalalgia. 1995 Oct;15Suppl 15:1-3. doi: 10.1111/J.1468-2982.1995.TB00040.X, PMID 8749238.
10. Rizzoli PB. Acute and preventive treatment of migraine. Continuum (Minneap Minn). 2012 Aug;18(4):764-82. doi: 10.1212/01.CON.0000418641.45522.3b, PMID 22868540.
11. Sidhu G, Preuss C, Patel P. Almotriptan. In: Treasure Island, FL: StatPearls; 2024 Jan 26. Available from: https://www.ncbi.nlm.nih.gov/books/NBK541092/#article-17383.s3. [Last accessed on 03 May 2025].
12. Abbas Z, Marihal S. Gellan gum-based mucoadhesive microspheres of almotriptan for nasal administration: formulation optimization using factorial design characterization and in vitro evaluation. J Pharm Bioallied Sci. 2014 Oct-Dec;6(4):267-77. doi: 10.4103/0975-7406.142959, PMID 25400410, PMCID PMC4231387.
13. Youssef NA, Kassem AA, Farid RM, Ismail FA, El Massik MA, Boraie NA. A novel nasal almotriptan-loaded solid lipid nanoparticles in mucoadhesive in situ gel formulation for brain targeting: preparation, characterization and in vivo evaluation. Int J Pharm. 2018 Sep 1;548(1):609-24. doi: 10.1016/j.ijpharm.2018.07.014, PMID 30033394.
14. Nair AB, Al Dhubiab BE, Shah J, Jacob S, Saraiya V, Attimarad M. Mucoadhesive buccal film of almotriptan improved therapeutic delivery in rabbit model. Saudi Pharm J. 2020 Feb;28(2):201-9. doi: 10.1016/j.jsps.2019.11.022, PMID 32042259, PMCID PMC6996216.
15. Verekar RR, Gurav SS, Bolmal U. Thermosensitive mucoadhesive in situ gel for intranasal delivery of Almotriptan malate: formulation characterization and evaluation. J Drug Deliv Sci Technol. 2020 Aug;58:101778. doi: 10.1016/j.jddst.2020.101778.
16. Medicine. Naratriptan Med Com. 2020 Feb 17. Available from: https://www.medicine.com/drug/naratriptan/hcp#pharmacology.
17. Omar SM, Abd Alla FI, Abdelgawad NM. Preparation and optimization of fast-disintegrating tablet containing naratriptan hydrochloride using D-optimal mixture design. AAPS PharmSciTech. 2018 Aug;19(6):2472-87. doi: 10.1208/s12249-018-1061-9, PMID 29869307.
18. Sattar M, Lane ME. Oral transmucosal delivery of naratriptan. Int J Pharm. 2016 Nov 30;514(1):263-9. doi: 10.1016/j.ijpharm.2016.06.039, PMID 27863671.
19. Shelke S, Shahi S, Jalalpure S, Dhamecha D, Shengule S. Formulation and evaluation of thermoreversible mucoadhesive in-situ gel for intranasal delivery of naratriptan hydrochloride. J Drug Deliv Sci Technol. 2015 Oct;29:238-44. doi: 10.1016/j.jddst.2015.08.003.
20. Kennewell PD. Antimigraine agents: triptans. In: Taylor JB, Triggle DJ, editors. Comprehensive medicinal chemistry II. Vol. 1. Amsterdam: Elsevier; 2007. p. 181-4.
21. Drug Bank. Rizatriptan. Drug Bank Online; 2021. Available from: https://www.drugbank.com/drugs/db00953.
22. Upadhyay J, Sonaji AV, Naaz F. Formulation & evaluation of anti Migrane mouth dissolving tablet. J Res Appl Sci Biotechnol. 2024 Apr;3(2):233-41. doi: 10.55544/jrasb.3.2.40.
23. Vidyadhara S, Sasidhar RL, Balakrishna T, Vardhan MS. Formulation of rizatriptan benzoate fast dissolving buccal films by emulsion evaporation technique. Int J Pharm Investig. 2015 Apr-Jun;5(2):101-6. doi: 10.4103/2230-973X.153387, PMID 25838995, PMCID PMC4381386.
24. Shirsat AE, Chitlange SS. Application of quality by design approach to optimize process and formulation parameters of rizatriptan-loaded chitosan nanoparticles. J Adv Pharm Technol Res. 2015 Jul-Sep;6(3):88-96. doi: 10.4103/2231-4040.157983, PMID 26317071, PMCID PMC4542404.
25. Guo X, Cun D, Wan F, Bera H, Song Q, Tian X. Comparative assessment of in vitro/in vivo performances of orodispersible electrospun and casting films containing rizatriptan benzoate. Eur J Pharm Biopharm. 2020;154:283-9. doi: 10.1016/j.ejpb.2020.06.023.
26. Salehi S, Boddohi S. New formulation and approach for mucoadhesive buccal film of rizatriptan benzoate. Prog Biomater. 2017 Dec;6(4):175-87. doi: 10.1007/s40204-017-0077-7, PMID 29110144, PMCID PMC5700911.
27. Suhagiya K, Borkhataria CH, Gohil S, Manek RA, Patel KA, Patel NK. Development of mucoadhesive in situ nasal gel formulation for enhanced bioavailability and efficacy of rizatriptan in migraine treatment. Results in Chemistry. 2023;6:101010. doi: 10.1016/j.rechem.2023.101010.
28. Chokshi A, Vaishya R, Inavolu R, Potta T. Intranasal spray formulation containing rizatriptan benzoate for the treatment of migraine. Int J Pharm. 2019 Nov 25;571:118702. doi: 10.1016/j.ijpharm.2019.118702, PMID 31593810.
29. Barbanti P, Le Pera D, Cruccu G. Sumatriptan fast disintegrating/rapid release tablets in the acute treatment of migraine. Expert Rev Neurother. 2007 Aug;7(8):927-34. doi: 10.1586/14737175.7.8.927, PMID 17678486.
30. Assadpour S, Akhtari J, Shiran MR. Pharmacokinetics study of chitosan coated liposomes containing sumatriptan in the treatment of migraine. Caspian J Intern Med. 2022;13(1):90-9. doi: 10.22088/cjim.13.1.90, PMID 35178213.
31. Kassab HJ, Alkufi HK, Hussein LS. Use of factorial design in formulation and evaluation of intrarectal in situ gel of sumatriptan. J Adv Pharm Technol Res. 2023 Apr-Jun;14(2):119-24. doi: 10.4103/japtr.japtr_603_22, PMID 37255866, PMCID PMC10226710.
32. Ronnander P, Simon L, Spilgies H, Koch A, Scherr S. Dissolving polyvinylpyrrolidone based microneedle systems for in vitro delivery of sumatriptan succinate. Eur J Pharm Sci. 2018 Mar 1;114:84-92. doi: 10.1016/j.ejps.2017.11.031, PMID 29203152.
33. Alavi S, Mortazavi SA. Freeze-dried K-carrageenan/chitosan polyelectrolyte complex-based insert: a novel intranasal delivery system for sumatriptan succinate. Iran J Pharm Res. 2018;17(4):1172-81. doi: 10.22037/ijpr.2018.2316, PMID 30568677, PMCID PMC6269572.
34. Masjedi M, Azadi A, Heidari R, Mohammadi Samani S. Nose-to-brain delivery of sumatriptan loaded nanostructured lipid carriers: preparation optimization, characterization and pharmacokinetic evaluation. J Pharm Pharmacol. 2020 Oct;72(10):1341-51. doi: 10.1111/jphp.13316, PMID 32579251, PMCID PMC7448981.
35. Gugulothu D, Desai P, Pandharipande P, Patravale V. Freeze drying: exploring potential in development of orodispersible tablets of sumatriptan succinate. Drug Dev Ind Pharm. 2015;41(3):398-405. doi: 10.3109/03639045.2013.871551, PMID 24384027.
36. Verma S, Tonk RK, Albratty M, Alhazmi HA, Najmi A, Kumar R. Design and evaluation of sustained release mucoadhesive film of sumatriptan succinate containing grafted co-polymer as the platform. Saudi Pharm J. 2022 Nov;30(11):1527-37. doi: 10.1016/j.jsps.2022.07.014, PMID 36465843.
37. Tepper SJ, Johnstone MR. Breath-powered sumatriptan dry nasal powder: an intranasal medication delivery system for acute treatment of migraine. Med Devices (Auckl). 2018 May 3;11:147-56. doi: 10.2147/MDER.S130900, PMID 29760572, PMCID PMC5937501.
38. Jelvehgari M, Valizadeh H, Ziapour S, Rahmani M, Montazam SH, Soltani S. Comparative study of different combinational mucoadhesive formulations of sumatriptan metoclopramide. Adv Pharm Bull. 2016 Mar 17;6(1):119-30. doi: 10.15171/apb.2016.018, PMID 27123427, PMCID PMC4845549.
39. Sasidhar RL, Vidyadhara S, Nagaraju R, Sowjanya Lakshmi B, Sailaja Y. Preparation and evaluation of sumatriptan succinate in situ gels. Int J Pharm Pharm Res. 2023 Feb 28;26(3):97-107.
40. Kulkarni NS, Yadav S, Patil S. Development of fast dissolving oral dosage form as tablet using binder as vigna mungo mucilage and oral film using solvent casting technique: comparative study. Asian J Pharm. 2023 Dec 5;17(4):754-62.
41. Drug Bank. Zolmitriptan. Drug Bank Online. Available from: https://www.drugbank.com/drugs/DB00315.
42. Kumar A, Garg T, Sarma GS, Rath G, Goyal AK. Optimization of combinational intranasal drug delivery system for the management of migraine by using statistical design. Eur J Pharm Sci. 2015 Apr 5;70:140-51. doi: 10.1016/j.ejps.2015.01.012, PMID 25676136.
43. El Taweel MM, Aboul Einien MH, Kassem MA, Elkasabgy NA. Intranasal zolmitriptan loaded bilosomes with extended nasal mucociliary transit time for direct nose to brain delivery. Pharmaceutics. 2021 Nov 1;13(11):1828. doi: 10.3390/pharmaceutics13111828, PMID 34834242.
44. Saleh A, Khalifa M, Shawky S, Bani Ali A, Eassa H. Zolmitriptan intranasal spanlastics for enhanced migraine treatment; formulation parameters optimized via quality by design approach. Sci Pharm. 2021 May 25;89(2):24. doi: 10.3390/scipharm89020024.
Published
How to Cite
Issue
Section
Copyright (c) 2025 TEJAL MEDANKAR, SHASHIKANT DHOLE, NILESH KULKARNI, AMISHA GHUGE
This work is licensed under a Creative Commons Attribution 4.0 International License.
